RecruitingNot ApplicableNCT05321316
Nectin-4 Specific LMW PET Probe Imaging in Urothelial Carcinoma
Sponsor
Peking University Cancer Hospital & Institute
Enrollment
20 participants
Start Date
May 31, 2026
Study Type
INTERVENTIONAL
Conditions
Summary
To evaluate the ability of \[68Ga\]N188 to detect nectin-4 overexpression in patients with urothelial carcinoma, especially in patients with recurrent or advanced bladder cancer.
Eligibility
Min Age: 18 YearsMax Age: 75 Years
Inclusion Criteria9
- 18-75 years old, male or female;
- Heart function is normal;
- Normal heart function;
- Estimated survival ≥12 weeks;
- Good follow-up compliance;
- presence of at least one measurable target lesion according to RECIST1.1 criteria;
- Women of childbearing age (15-49 years) must have a negative pregnancy test within 7 days before starting the test; Fertile men and women must agree to use effective contraception to prevent pregnancy during the study period and for 3 months after the test;
- Patients recommended by clinicians to undergo PET/CT examination for tumor diagnostic staging;
- The subject patients could fully understand and voluntarily participate in the experiment, and signed the informed consent.
Exclusion Criteria4
- Serious abnormality of liver, kidney and blood;
- Pregnant patients;
- Pregnant and lactation women;
- \) unable to lie flat for half an hour; 4) Refuse to join the clinical investigator; 5) Suffering from claustrophobia or other mental diseases; 6) Other conditions that researchers deem unsuitable for participating in the experiment.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUG18F-FDG
All study participants will undergo one 18F-FDG PET/CT scan.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05321316
Related Trials
A Study of GEN1106 in Participants With Solid Tumors
NCT074161233 locations
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
NCT0709049928 locations
Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
NCT0742170025 locations
Trastuzumab in Combination With Serplulimab and Chemotherapy for the Treatment of HER2-overexpressing Unresectable Locally Advanced or Metastatic Biliary Tract Cancer or Urothelial Carcinoma After Failure of Standard Therapy
NCT075060571 location
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
NCT0629389817 locations